Microencapsulated drug delivery: a new approach to pro-inflammatory cytokine inhibition

Oettinger, Carl W.; D’Souza, Martin J.

doi:10.3109/02652048.2012.658443

Cited by 7 publications

(6 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…50 Microencapsulated compounds of antioxidant enzyme catalase inhibited hydrogen peroxide production, nitrate synthesis and TNF release in cell culture models using endothelial cells. 51 Therefore, catalase also plays an important role in suppression of inflammation. Thus, we propose that there may be two possible pathways through which fullerol nanoparticles prevented cellular inflammatory responses.…”

Section: Discussionmentioning

confidence: 99%

Novel Treatment of Neuroinflammation Against Low Back Pain by Soluble Fullerol Nanoparticles

Liu

Jin

Mahon

et al. 2013

Spine

View full text Add to dashboard Cite

Study Design An in vitro study to investigate the anti-inflammatory effects of fullerol on mouse dorsal root ganglia (DRG) under TNF-α induction. Objective To evaluate the potential of a free radical scavenger, fullerol nanoparticles, to prevent DRG tissue and neuron inflammatory responses under TNF-α induction in vitro. Summary of Background Data Low back pain is one of the most common reasons for clinician visits in western societies. Symptomatic intervertebral disc (IVD) degeneration is strongly implicated as a cause of low back pain as it results in DRG inflammation. Increased production of reactive oxygen species (ROS) is associated with DRG inflammation. Methods With or without fullerol treatment, DRG tissue and DRG neurons isolated from wild type C3H/HeNCrl mice were cultured under TNF-α induction. The amount of intracellular ROS was measured with H2DCFDA fluorescence staining. Cellular apoptosis was detected via terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay. The expression of inflammatory as well as anti-oxidative enzyme genes in neurons was analyzed by real-time PCR. In addition, inflammatory cytokine expression in DRG tissue was determined by immunofluorescence staining and enzyme-linked immunosorbent assay (ELISA). Results Fluorescence staining results indicated that TNF-α markedly increased the production of intracellular ROS and the number of apoptotic cells. Under fullerol treatment cellular apoptosis was reduced along with concomitant suppression of ROS. The expression of inflammatory cytokines IL-1 β, IL-6, COX-2, and PGE2, was also inhibited by fullerol in a dose-dependent manner. Furthermore, fullerol-treated cells exhibited up-regulation of anti-oxidative enzyme genes SOD2 and catalase. Conclusion The results obtained from this study clearly suggest that fullerol treatment suppresses the inflammatory responses of DRG and neurons, as well as cellular apoptosis by decreasing the level of ROS and potentially enhancing anti-oxidative enzyme gene expression. Therefore, fullerol has potential to serve as a novel therapeutic agent for low back pain treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Novel Treatment of Neuroinflammation Against Low Back Pain by Soluble Fullerol Nanoparticles

Liu

Jin

Mahon

et al. 2013

Spine

View full text Add to dashboard Cite

show abstract

“…Core–shell structure of albumin nanocapsules is developed as carriers for delivery of anti-inflammatory drugs [78]. Since the fundamental role of activated synovial macrophages in rheumatoid arthritis, an inflammatory disease, in a study, Rollett et al designed a nanodevice using folic acid (FA)-functionalized HSA nanocapsules to reduce macrophage populations without side effects on normal tissues [79].…”

Section: Albumin Nanostructuresmentioning

confidence: 99%

Albumin nanostructures as advanced drug delivery systems

Karimi

Bahrami

Ravari

et al. 2016

Expert Opinion on Drug Delivery

333

190

View full text Add to dashboard Cite

Introduction One of the biggest impacts that the nanotechnology has made on medicine and biology, has been in the area of drug delivery systems (DDSs). Many drugs suffer from serious problems concerning insolubility, instability in biological environments, poor uptake into cells and tissues, suboptimal selectivity for targets and unwanted side effects. Nanocarriers can be designed as DDSs to overcome many of these drawbacks. One of the most versatile building blocks to prepare these nanocarriers is the ubiquitous, readily available and inexpensive protein, serum albumin. Areas covered This review covers the use of different types of albumin (human, bovine, rat, and chicken egg) to prepare nanoparticle and microparticle-based structures to bind drugs. Various methods have been used to modify the albumin structure. A range of targeting ligands can be attached to the albumin that can be recognized by specific cell receptors that are expressed on target cells or tissues. Expert opinion The particular advantages of albumin used in DDSs include ready availability, ease of chemical modification, good biocompatibility, and low immunogenicity. The regulatory approvals that have been received for several albumin-based therapeutic agents suggest that this approach will continue to be successfully explored.

show abstract

“…Urokinase has been immobilized in GA cross-linked bovine serum albumin (BSA) particles by Bhargava and Ando, 27 and GA cross-linked insulin-BSA microbeads were prepared by Goosen et al 28 Human serum albumin (HSA) nanocapsules were prepared by Rollett et al 29 for targeted drug delivery to activated macrophages. Application of albumin microspheres (3–4 μ m) to pro-inflammatory cytokine inhibition was reviewed by Oettinger and D’Souza, 30 and versatility of albumin as a drug carrier was evaluated by Kratz. 31 Doshi and Mitragotri 32 demonstrated that both size and shape of polymeric particles critically control their elimination by macrophages.…”

Section: Introductionmentioning

confidence: 99%

Silylated Precision Particles for Controlled Release of Proteins

Khodabandehlou

Kumbhar

Habibi

et al. 2015

ACS Appl. Mater. Interfaces

View full text Add to dashboard Cite

With the recent advances in the development of novel protein based therapeutics, controlled delivery of these biologics is an important area of research. Herein, we report the synthesis of microparticles from bovine serum albumin (BSA) as a model protein using Particle Replication in Non-wetting Templates (PRINT) with specific size and shape. These particles were functionalized at room temperature using multifunctional chlorosilane that cross-link the particles to render them to slowly-dissolving in aqueous media. Mass spectrometric study of the reaction products of diisopropyldichlorosilane with individual components of the particles revealed that they are capable of reacting and forming cross-links. Energy dispersive spectroscopy (EDS) and X-ray photoelectron spectroscopy (XPS) were also used to confirm the functionalization of the particles. Cross sectional analysis using focused ion beam (FIB) and EDS proved that the functionalization occurs throughout the bulk of the particles and is not just limited to the surface. Circular dichroism data confirmed that the fraction of BSA molecules released from the particles retains its secondary structure thereby indicating that the system can be used for delivering protein based formulations while controlling the dissolution kinetics.

show abstract

Microencapsulated drug delivery: a new approach to pro-inflammatory cytokine inhibition

Cited by 7 publications

References 38 publications

Novel Treatment of Neuroinflammation Against Low Back Pain by Soluble Fullerol Nanoparticles

Novel Treatment of Neuroinflammation Against Low Back Pain by Soluble Fullerol Nanoparticles

Albumin nanostructures as advanced drug delivery systems

Silylated Precision Particles for Controlled Release of Proteins

Contact Info

Product

Resources

About